Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$433.74
+5.33%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+12.3%
3 months
+12.7%
6 months
+58.5%
1 year
+75.0%
Year to date
+71.0%
52-week range
$162.10 – $433.74
Latest reported period: Sep 30, 2026
Market cap
$52.09B
P/E
41.8
P/B
2.8
P/S
0.3
Revenue
$154.19B
Net income
$1.25B
Diluted EPS
10.3
Gross margin
13.00%
Net margin
0.80%
Return on equity
6.70%
Total debt
$12.82B
Cash
$6.94B
Free cash flow
$3.16B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $41.16B | $162M | 11.70% | 0.40% | $2.03B |
| Jun 30, 2026 | $40.87B | $694M | 13.50% | 1.70% | $1.83B |
| Mar 31, 2026 | $39.65B | $1.19B | 15.00% | 3.00% | $1.13B |
| Dec 31, 2025 | $32.52B | -$796M | 11.70% | -2.40% | -$1.83B |
| Sep 30, 2025 | $32.65B | $195M | 14.30% | 0.60% | $836M |
| Jun 30, 2025 | $32.39B | $545M | 14.90% | 1.70% | $1.16B |
| Mar 31, 2025 | $32.11B | $1.24B | 17.40% | 3.90% | $236M |
| Dec 31, 2024 | $29.21B | -$693M | 13.10% | -2.40% | -$675M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
More seniors than expected signing up for Humana’s plans in 2026 was a major concern for investors. But Humana is in a much better position to absorb future growing pains, executives said.
Original sourceHumana Inc. (NYSE: HUM) reported its third-quarter 2026 financial results, with GAAP earnings per share of $1.33 and an adjusted loss per share of $0.70. The company also raised its full-year 2026 adjusted EPS guidance to "at least $9.50" from "at least $9.00," and its GAAP EPS guidance to "at least $15.09" from "at least $6.52". Key growth areas included a 30% increase in CenterWell Senior Primary Care patients and a 7% rise in Medicaid membership.
Original sourceBank Julius Baer & Co. Ltd Zurich has acquired a new stake in Humana Inc. (NYSE:HUM) during the third quarter, purchasing 3,065 shares valued at approximately $1,186,000. Several other institutional investors also modified their holdings, with analysts issuing new price targets and maintaining a "Moderate Buy" consensus rating for the insurance provider. Humana recently announced a quarterly dividend of $0.8850, payable on January 29th, 2027.
Original sourceArgus has raised its price target for Tenet Healthcare Corporation (THC) to $293.00, citing the company's strong position in healthcare services. As of November 4, 2026, THC's current price is $292.25. Tenet Healthcare operates 47 acute and specialty hospitals and over 500 ambulatory surgery centers across the U.S., predominantly in the South.
Original sourceIntuitive Surgical Inc. announced the appointment of Aaron Martin, President of Insurance at Humana, to its board of directors, effective January 1, 2027. Martin's extensive background in healthcare technology, leadership, and insurance operations is expected to bolster Intuitive's mission to broaden access to minimally invasive care. This addition expands Intuitive's board from 10 to 11 members.
Original sourceCVS Health is suing the federal government to challenge its 2027 Medicare Advantage star ratings, aiming to avert a potential revenue loss exceeding $2 billion due to declining quality scores. The lawsuit argues that the CMS used illegal methodology and improperly adopted measures to calculate the ratings. CVS joins at least four other insurers in similar lawsuits, all citing a previous ruling that found CMS measures for 2026 scores to be illegal.
Original source